In one of those “only in cannabis policy” twists, the federal government is moving toward covering CBD under a national health insurance plan—while potentially allowing products that blow past the usual THC limits.
Yeah, that contradiction is real.
A new Medicare-style pilot program is being built to give patients access to CBD products with a doctor’s recommendation—marking a huge shift in federal policy after years of saying “absolutely not.”
But here’s where things get weird.
Even though federal law still defines hemp as containing no more than 0.3% THC—and new rules are actually tightening limits on finished products—this program could allow certain full-spectrum CBD products that naturally carry higher THC levels.
So on one hand:
The government is cracking down on THC in hemp products nationwide.
On the other:
It’s opening the door for patients to access cannabinoid products that may not fit neatly into those same limits.
Welcome to cannabis regulation—where the rules don’t always agree with each other.
Zoom out, and the bigger picture starts to make sense.
This all stems from a broader push under Donald Trump to expand cannabis research, reschedule marijuana, and explore CBD as a legitimate medical option.
The result? Progress… with a side of policy chaos.
Because while Washington is finally warming up to cannabinoids in healthcare, it’s still trying to figure out how to define, regulate, and limit them—all at the same time.
So patients may soon get federally supported CBD access…
Even if the rulebook says that same product shouldn’t exist.
Dabbin-Dad Newsroom
